The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. RVL Pharmaceuticals's Revenue for the
three
months ended in Jun. 2023 was $8.26 Mil. RVL Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2023 was $0.51 Mil.
Hence, RVL Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2023 was 16.32.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
RVL Pharmaceuticals Receivables Turnover Related Terms
RVL Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for RVL Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVLPQ vs SNPX, THAR, SLRX: Receivables Turnover Comparison
For the Biotechnology subindustry, RVL Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RVL Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where RVL Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVL Pharmaceuticals (RVLPQ) has a Receivables Turnover of 16.32 as of Jun. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' Receivables Turnover too high?
RVL Pharmaceuticals' current Receivables Turnover is 16.32. The Biotechnology industry median Receivables Turnover is 5.28. RVL Pharmaceuticals' value of 16.32 is 209.4% above this industry median. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Receivables Turnover compare to SNPX and THAR?
RVL Pharmaceuticals' Receivables Turnover of 16.32 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. RVL Pharmaceuticals' value of 16.32 is 209.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RVL Pharmaceuticals's current Receivables Turnover of 16.32 is 209.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RVL Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RVL Pharmaceuticals's current Receivables Turnover is 16.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Receivables Turnover of 16.32. The current Receivables Turnover is 16.32 and 209.4% above the Biotechnology industry median of 5.28. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Receivables Turnover is 16.32 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score
Get the complete analysis for RVLPQ
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVLPQ has been successfully added to your 
